Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Post by BearDownAZon Aug 09, 2016 2:06pm
240 Views
Post# 25123372

Has biOasis done any primate studies with Mtf or Mtfp?

Has biOasis done any primate studies with Mtf or Mtfp?

Digitel asked a series of questions last week asking whether there have been studies of long-term (>1 yr) administration of Mtf or Mtfp or if studies have been performed in a higher order mammal. To the best of my knowledge, which is very limited since I haven't followed biOasis as long as many of you, the longest disclosed studies of Mtf or Mtfp administration have been 5 weeks (Herceptin/Trastuzumab) or 6 weeks (Idursulfase/I2S). I have no problem with this. The goal of those rodent studies was to show that transport and efficacy across the blood brain barrier was achieved. Check.

To the best of my limited knowledge, all disclosed studies have been in cells or in mice. It would be quite surprising to me if biOasis goes directly from mice to humans without any other studies in other animal models. Furthermore, I expect that a non-human primate model would be utilized by biOasis prior to proceeding to human studies. For example, Armagen has done studies in Rhesus macaque primates prior to proceeding to human studies. So with the rumored talk of a Phase 0 human study and biOasis taking the Herceptin/Trastuzumab program to the clinic on their own, the question about validation in other animal models is very relevant. I posted this message to Agoracom last week, but it's pretty quiet over there and didnt' get a response. I'd be interested to hear others opinions on this on the Stockhouse board.

Best regards,

BearDownAZ

Bullboard Posts